Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Other Operating Expenses: 2009-2025

Historic Other Operating Expenses for Cumberland Pharmaceuticals (CPIX) over the last 17 years, with Sep 2025 value amounting to $6.4 million.

  • Cumberland Pharmaceuticals' Other Operating Expenses fell 5.39% to $6.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.0 million, marking a year-over-year decrease of 11.20%. This contributed to the annual value of $28.4 million for FY2024, which is 5869.95% up from last year.
  • Latest data reveals that Cumberland Pharmaceuticals reported Other Operating Expenses of $6.4 million as of Q3 2025, which was down 11.18% from $7.2 million recorded in Q2 2025.
  • Cumberland Pharmaceuticals' 5-year Other Operating Expenses high stood at $10.8 million for Q4 2023, and its period low was $6.1 million during Q3 2021.
  • For the 3-year period, Cumberland Pharmaceuticals' Other Operating Expenses averaged around $7.4 million, with its median value being $7.1 million (2024).
  • In the last 5 years, Cumberland Pharmaceuticals' Other Operating Expenses surged by 66.90% in 2023 and then declined by 29.27% in 2024.
  • Over the past 5 years, Cumberland Pharmaceuticals' Other Operating Expenses (Quarterly) stood at $7.6 million in 2021, then decreased by 15.17% to $6.5 million in 2022, then soared by 66.90% to $10.8 million in 2023, then decreased by 29.27% to $7.7 million in 2024, then decreased by 5.39% to $6.4 million in 2025.
  • Its last three reported values are $6.4 million in Q3 2025, $7.2 million for Q2 2025, and $6.7 million during Q1 2025.